Full-Time

Staff Accountant

Updated on 9/4/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$77k - $100k/yr

Stamford, CT, USA

Hybrid

At least two days on-site per week, currently Tuesday and Wednesday; additional on-site days may be required.

Bachelor's

Category
Accounting (1)
Required Skills
NetSuite
QuickBooks
Excel/Numbers/Sheets

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • Bachelor's degree in Accounting or Finance.
  • Three years of accounting experience in a corporate, public accounting, or life sciences environment.
  • Foundational knowledge of United States generally accepted accounting principles, including accrual accounting, reconciliation preparation, journal entry documentation, and basic financial statement concepts.
  • Proficiency in Microsoft Excel, including the ability to prepare and maintain accounting schedules, reconciliations, and supporting workpapers; experience with VLOOKUP, pivot tables, and basic financial formulas.
  • Familiarity with accounting software or enterprise resource planning systems such as NetSuite, QuickBooks, or equivalent.
  • Strong attention to detail and organizational skills, with the ability to manage multiple accounting tasks simultaneously, meet close deadlines consistently, and maintain accurate and organized financial records.
  • Ability to consistently meet deadlines, follow through on assigned responsibilities, and communicate proactively when issues or questions arise.
  • Ability to identify opportunities to work more efficiently, maintain better documentation, and contribute to a higher-quality accounting close process.
  • Ability to correspond with vendors, internal stakeholders, and Finance team members in a professional, organized, and timely manner.
  • Ability to respond to questions and requests from the Finance team, external auditors, and cross-functional partners in a timely, professional, and helpful manner.
Responsibilities
  • Support the monthly financial close process by preparing and posting journal entries, performing account reconciliations, and assisting with close workpapers for prepaid expenses, accruals, and fixed assets.
  • Process and manage accounts payable activities by reviewing and coding vendor invoices, coordinating approval workflows, maintaining vendor records, and supporting timely and accurate payment processing in accordance with company policies.
  • Prepare and maintain accounting schedules and supporting documentation for assigned balance sheet accounts, ensuring reconciliations are accurate, timely, and supported by appropriate backup documentation.
  • Support clinical and research program accrual processes by working with Clinical Operations, Finance, and external vendors to track program expenditures, estimate accruals, and accurately record contract research organization and research-related costs.
  • Assist in preparing external audit support by organizing workpapers, preparing schedules, and gathering documentation in response to auditor requests under the direction of the Manager, Accounting.
  • Support accounts payable vendor management by maintaining vendor master data, processing new vendor setups, and ensuring W-9/W-8 compliance in coordination with Tax and Finance leadership.
  • Contribute to continuous improvement of accounting processes by identifying opportunities to streamline workflows, improve documentation standards, and enhance the efficiency of close and reporting activities.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • CPA exam eligibility or active progress toward CPA licensure.
  • Experience with general ledger accounting, accounts payable, or financial close processes.
  • Life sciences or biotechnology experience.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...